Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125799703 | 12579970 | 3 | F | 20160302 | 20160913 | 20160721 | 20160915 | EXP | GB-TAKEDA-2016MPI006522 | TAKEDA | 71.00 | YR | F | Y | 57.00000 | KG | 20160915 | MD | GB | GB |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125799703 | 12579970 | 1 | PS | VELCADE | BORTEZOMIB | 1 | Subcutaneous | 1.3 MG/M2, UNK | Y | 21602 | 1.3 | MG/M**2 | INJECTION | ||||||
125799703 | 12579970 | 2 | SS | VELCADE | BORTEZOMIB | 1 | Subcutaneous | 1.3 MG/M2, UNK | Y | 21602 | 1.3 | MG/M**2 | INJECTION | ||||||
125799703 | 12579970 | 3 | SS | VELCADE | BORTEZOMIB | 1 | Subcutaneous | 1.3 MG/M2, UNK | Y | 21602 | 1.3 | MG/M**2 | INJECTION | ||||||
125799703 | 12579970 | 4 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 20 MG, UNK | Y | 0 | 20 | MG | |||||||
125799703 | 12579970 | 5 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 20 MG, UNK | Y | 0 | 20 | MG | |||||||
125799703 | 12579970 | 6 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 12 MG, UNK | Y | 0 | 12 | MG | |||||||
125799703 | 12579970 | 7 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 2.857 MG, 1/WEEK | Y | 0 | 2.857 | MG | /wk | ||||||
125799703 | 12579970 | 8 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | Oral | 75 MG, QD | 0 | 75 | MG | QD | |||||||
125799703 | 12579970 | 9 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | Oral | 75 MG, QD | 0 | 75 | MG | QD | |||||||
125799703 | 12579970 | 10 | C | PAMIDRONATE | PAMIDRONATE DISODIUM | 1 | Intravenous (not otherwise specified) | 3 MG, MONTHLY | 0 | 3 | MG | /month | |||||||
125799703 | 12579970 | 11 | C | ALLOPURINOL. | ALLOPURINOL | 1 | Oral | 300 MG, QD | 0 | 300 | MG | QD | |||||||
125799703 | 12579970 | 12 | C | ALLOPURINOL. | ALLOPURINOL | 1 | Oral | 300 MG, QD | 0 | 300 | MG | QD | |||||||
125799703 | 12579970 | 13 | C | ACYCLOVIR /00587301/ | ACYCLOVIR | 1 | Oral | 800 MG, BID | 0 | 800 | MG | BID | |||||||
125799703 | 12579970 | 14 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 30 MG, QD | 0 | 30 | MG | QD | |||||||
125799703 | 12579970 | 15 | C | DOXYCYCLINE. | DOXYCYCLINE | 1 | Oral | 100 MG, QD | 0 | 100 | MG | QD | |||||||
125799703 | 12579970 | 16 | C | CO-AMOXICLAVE | AMOXICILLINCLAVULANATE POTASSIUM | 1 | Oral | 1875 MG, TID | 0 | 1875 | MG | TID | |||||||
125799703 | 12579970 | 17 | C | TINZAPARIN | TINZAPARIN | 1 | Oral | UNK, QD | 0 | QD | |||||||||
125799703 | 12579970 | 18 | C | TINZAPARIN | TINZAPARIN | 1 | Subcutaneous | UNK, QD | 0 | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125799703 | 12579970 | 1 | Plasma cell myeloma |
125799703 | 12579970 | 4 | Plasma cell myeloma |
125799703 | 12579970 | 8 | Prophylaxis |
125799703 | 12579970 | 10 | Prophylaxis |
125799703 | 12579970 | 11 | Prophylaxis |
125799703 | 12579970 | 12 | Tumour lysis syndrome |
125799703 | 12579970 | 13 | Antiviral prophylaxis |
125799703 | 12579970 | 14 | Dyspepsia |
125799703 | 12579970 | 15 | Respiratory disorder |
125799703 | 12579970 | 16 | Respiratory disorder |
125799703 | 12579970 | 17 | Deep vein thrombosis |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125799703 | 12579970 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125799703 | 12579970 | Alopecia | |
125799703 | 12579970 | Blood glucose increased | |
125799703 | 12579970 | Blood phosphorus decreased | |
125799703 | 12579970 | Blood potassium decreased | |
125799703 | 12579970 | Confusional state | |
125799703 | 12579970 | Constipation | |
125799703 | 12579970 | Cough | |
125799703 | 12579970 | Depressed mood | |
125799703 | 12579970 | Diarrhoea | |
125799703 | 12579970 | Dizziness | |
125799703 | 12579970 | Dyspepsia | |
125799703 | 12579970 | Erythema | |
125799703 | 12579970 | Fatigue | |
125799703 | 12579970 | Headache | |
125799703 | 12579970 | Hypotension | |
125799703 | 12579970 | Injection site erythema | |
125799703 | 12579970 | Muscle spasms | |
125799703 | 12579970 | Myalgia | |
125799703 | 12579970 | Nausea | |
125799703 | 12579970 | Pyrexia | |
125799703 | 12579970 | Respiratory disorder | |
125799703 | 12579970 | Respiratory tract infection viral | |
125799703 | 12579970 | Synovial cyst | |
125799703 | 12579970 | Tearfulness | |
125799703 | 12579970 | Thirst | |
125799703 | 12579970 | Urinary tract infection | |
125799703 | 12579970 | Vision blurred |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125799703 | 12579970 | 1 | 20160229 | 20160320 | 0 | |
125799703 | 12579970 | 2 | 20160418 | 20160509 | 0 | |
125799703 | 12579970 | 3 | 20160516 | 20160526 | 0 | |
125799703 | 12579970 | 4 | 20160229 | 20160320 | 0 | |
125799703 | 12579970 | 5 | 20160418 | 20160509 | 0 | |
125799703 | 12579970 | 6 | 20160416 | 20160601 | 0 | |
125799703 | 12579970 | 7 | 20160630 | 0 | ||
125799703 | 12579970 | 8 | 2014 | 0 | ||
125799703 | 12579970 | 9 | 20160502 | 0 | ||
125799703 | 12579970 | 10 | 20131210 | 0 | ||
125799703 | 12579970 | 11 | 20160229 | 0 | ||
125799703 | 12579970 | 12 | 20160229 | 0 | ||
125799703 | 12579970 | 13 | 20160229 | 0 | ||
125799703 | 12579970 | 14 | 20160307 | 0 | ||
125799703 | 12579970 | 15 | 20160329 | 0 | ||
125799703 | 12579970 | 16 | 20160425 | 0 | ||
125799703 | 12579970 | 17 | 20160407 | 20160407 | 0 | |
125799703 | 12579970 | 18 | 20160519 | 20160519 | 0 |